EDITY THERAPEUTICS
EdiTy Therapeutics is a biotechnology company that develops a gene-editing technology designed for in-vivo gene-editing of target cells. It utilizes T-cells machinery to directly deliver gene-editing agents to target cells in-vivo. Yoav Manaster established the Ness Ziona, HaMerkaz, Israel-based company in 2020.
EDITY THERAPEUTICS
Social Links:
Industry:
Biotechnology Genetics Medical Device Therapeutics
Founded:
2020-01-01
Address:
Ness Ziona, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.edity-tx.com
Total Employee:
1+
Status:
Closed
Total Funding:
0
Current Employees Featured
Founder
Investors List
Tal Ventures
Tal Ventures investment in Seed Round - EdiTy Therapeutics
Roy Oron
Roy Oron investment in Pre Seed Round - EdiTy Therapeutics
Official Site Inspections
http://www.edity-tx.com
- Host name: 206.100.189.35.bc.googleusercontent.com
- IP address: 35.189.100.206
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "EdiTy Therapeutics"
Home - Edity Therapeutics
Edity Therapeutics - Cellular Re-programming utilizing the Immune system : We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity. ... [email protected]. 10 Menachem …See details»
EdiTy Therapeutics - Crunchbase Company Profile
Organization. EdiTy Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... www.edity-tx.com ; …See details»
Edity - Company Profile - Tracxn
Nov 29, 2024 Edity - Developer of a drug delivery platform based on gene-editing technology. Raised funding from 2 investors. Founded by Yoav Manaster in the year 2020. Edity has 158 …See details»
Edity Therapeutics - LinkedIn
Edity is developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Our technology allows for precise modulation of intracellular ...See details»
EDITY THERAPEUTICS LTD Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for EDITY THERAPEUTICS LTD of REHOVOT, Shfella Area. Get the latest business insights from Dun …See details»
Edity Therapeutics Ltd.: Drug pipelines, Patents, Clinical trials
Jul 3, 2023 Explore Edity Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
Edity Therapeutics LTD Details - govtribe.com
- https://edity-tx.com. Twitter Using human immune cells to deliver therapeutic proteins - Twitter. Metrics Founded 2020 Employees Range 11-50 Number of Employees 30 ... Phone numbers …See details»
Edity Therapeutics - PitchBook
Edity Therapeutics General Information Description. Operator of a biotechnology company intended to deliver protein therapeutics for patients. The company harnesses the immune system to deliver therapeutic proteins directly to the …See details»
Edity - Overview, News & Similar companies | ZoomInfo.com
Dec 29, 2023 View Edity (www.edity-tx.com) location in Israel , revenue, industry and description. Find related and similar companies as well as employees by title and much more. …See details»
EdiTy Therapeutics - VentureRadar
EdiTy Therapeutics is developing the next-generation delivery of gene-editing. ... Find out more about EdiTy Therapeutics including the VentureRadar Innovation and Growth scores, Similar …See details»
Edity Therapeutics Company Profile: , Investments, Contact …
Edity is developing a novel delivery platform that uses immune cells to transfer therapeutic proteins to the target cells of patients. Our technology allows for precise modulation of …See details»
Edity’s Competitors, Revenue, Number of Employees, Funding
Edity’s Profile, Revenue and Employees. Edity is an Israel-based biotechnology company that develops a pre-clinical platform to deliver therapeutic proteins for the treatment of cancer, and …See details»
EdiTy Therapeutics - TAL Ventures
EdiTy develops precision therapeutics for the genomic age, enabling targeted deployment of gene editing against diseases that are currently beyond the capabilities of modern medicine. At our …See details»
Aurigene Pharmaceutical Services Limited, a global CRDMO, and …
Jul 2, 2024 Edity® Therapeutics has developed a proprietary platform for the selective delivery of intracellular proteins to diseased tissues and is creating new cellular medicines with curative …See details»
Aurigene Pharmaceutical Services Limited, a global CRDMO, and …
Aurigene is a global contract research, development, and manufacturing organization (CRDMO), Dr. Reddy’s company, built on the legacy of accelerating innovation and backed by a vast …See details»
Aurigene Pharmaceutical Services Limited, a global CRDMO, and …
Hyderabad, India. July 01, 2024: Aurigene Pharmaceutical Services Limited (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), will …See details»
Edity Therapeutics - Foreign Startup | Startup Nation Finder
Jan 16, 2024 Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue …See details»
Meet 007: The cell with a license to kill cancer, created by
Jul 31, 2023 Edity has also received non diluted funding from the Israel Innovation Authority. Edity is now raising a funding round on the OurCrowd global investing platform. Edity’s trial of …See details»
Edity Therapeutics enters into a Strategic Collaboration with Dr.
Jan 16, 2024 Edity Therapeutics announced a strategic collaboration with Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along …See details»
Triggering immune response from within cancer cells - poster
Edity cell With engineered protein Modulate disease by ACT INTRODUCTION The perforin-granzyme pathway delivers lytic payloads into target cells anywhere in the body with supreme …See details»